InvestorsHub Logo
Followers 4
Posts 579
Boards Moderated 0
Alias Born 04/14/2001

Re: Patricia_1 post# 128

Wednesday, 03/24/2004 10:36:15 AM

Wednesday, March 24, 2004 10:36:15 AM

Post# of 141
3/26/04 update to Multicell/Xenotech Conferences in 2004

Thanks to seatech3 at the EXTI RB thread

Conferences/Journals this year (12 and counting)

1. Jan 13, 2004 - Journal of Pharmacology and Experimental Therapeutics
http://intl-jpet.aspetjournals.org/cgi/content/abstract/jpet.103.061713v1

Induction of drug metabolizing enzymes and MDR1 using a novel hepatocyte cell line
Jessica B Mills 1, Kelly Rose 1, Nalini Sadagopan 1, Jasminder Sahi 1, Sonia M. F. de Morais 1*

Pfizer Global Research and Development

"Induction of drug metabolizing enzymes and transporters can cause drug-drug interactions and loss of efficacy. In vitro induction studies traditionally use primary hepatocyte cultures and enzyme activity with selected marker compounds. We investigated the use of a novel human hepatocyte clone, the Fa2N-4 cell line, as an alternative reagent, which is readily available and provides a consistent, reproducible system. We used the Invader® assay to monitor gene expression in these cells. This assay is a robust, yet simple, high-throughput system for quantification of mRNA transcripts. CYP1A2, CYP3A4, CYP2C9, UGT1A, and MDR1 transcripts were quantified from total RNA extracts from Fa2N-4 cells treated with a panel of known inducers and compared with vehicle controls. In addition, we used enzyme activity assays to monitor the induction of CYP1A2, CYP2C9, and CYP3A4. The Fa2N-4 cells responded in a similar manner as primary human hepatocytes. Treatment with 10 µM rifampin resulted in increases in CYP3A4 mRNA (17-fold) and activity (6-beta-hydroxytestoterone formation, 9-fold); and in CYP2C9 mRNA (4-fold) and activity (4'-hydroxydiclofenac formation, 2-fold). Treatment with 50 µM beta-naphthoflavone resulted in increases in CYP1A2 mRNA (15-fold) and activity (7-ethoxyresorufin O-dealkylation, 27-fold). UGT1A mRNA was induced by beta-naphthoflavone (2-fold), and MDR1 (P-glycoprotein) mRNA was induced by rifampin (3-fold). These preliminary data using a few prototypical inducers show that Fa2N-4 cells can be a reliable surrogate for primary human hepatocytes, and, when used in conjunction with the Invader® technology, could provide a reliable assay for assessment of induction of drug metabolizing enzymes and transporters."

2. Feb 11, 2004 - Annual Forum on ADME/Tox
http://www.cbinet.com/events/HB405/day_one.html

2:15 Induction of Major Cytochrome P450 Enzymes in Immortalized Human Hepatocytes
Primary cultures of human hepatocytes are the most suitable test system to evaluate induction of drug metabolizing enzymes by New Chemical Entities (NCEs). The supply of human livers available for support of drug development though is increasingly limited and their response to NCE’s is highly variable due to numerous environmental and genetic factors. Recently, SV40 T Ag-immortalized hepatocytes, Fa2N-4, demonstrated cytochrome P450 (CYP) enzyme’s activity and inducibility, among other characteristics of differentiated liver functions. Since these cells can be cryopreserved and are readily available, they constitute a test system alternative to primary cultures of hepatocytes. This session discusses the data from two independent laboratories who have characterized the activity of multiple CYP in response to prototypical enzyme inducers, which regulate gene expression through distinctive nuclear receptor pathways.
• Cultured with a uniquely formulated media, these cells grow and maintain their functions in 96-well plates
• Cell culture and LC/MS/MS methods were developed to ascertain inductive potential of NCEs with Fa2N-4 cells

Jessica B. Mills, Ph.D., Associate Scientist, Pfizer Inc
Andrew Parkinson, Ph.D., President and CEO, XenoTech LLC

XenoTech will also sponsor an exhibit at this meeting.

3. IBC's Preclinical Development Forum
Feb 23 - 25, 2004
Cambridge, MA

XenoTech will sponsor an exhibit at this conference.

4. ISE's 4th International Conference on Early Toxicity Screening
Feb 23 - 24, 2004
San Diego, CA

Presentation by Dr. Andrew Parkinson, XenoTech CEO
Session 2
"Immortalized Hepatocytes: A New In Vitro Approach to Early Induction and Hepatotoxicity Screening

XenoTech will also sponsor an exhibit at this conference

5. ECPM Course: Toxicology and Clinical Pharmacology
March 8 - 10, 2004
Basel, Switzerland
Andrew Parkinson, Ph.D. will lecture on the topic of Drug Metabolism in Health and Disease.

6. Wednesday, March 24, 2004 Society of Toxicology Annual Meeting
http://www.toxicology.org/memberservices/meetings/am2004/

1:30 - 4:30 p.m. - THE USE OF IMMORTALIZED HEPATOCYTES IN METABOLISM AND INDUCTION STUDIES
Kevin C. Lyon, XenoTech

7. Cell-Based Assays For HTS
May 17-18, 2004, Philadelphia, Pennsylvania

Break-Through Technologies

9:55-10:10 Immortalized Hepatocytes: A New In Vitro Approach to Early Compound Screening
Andrew Parkinson, Ph.D., Chief Executive Officer, XenoTech, LLC
A new human hepatocyte cell line has the potential to solve the problem of supply and inter-individual variability that restrict the use of human hepatocytes for candidate comparisons in preclinical metabolism, toxicity, and induction studies. Its unlimited supply assures long-term reproducibility and scheduling convenience in utilizing this breakthrough technology.

8. May 19(Wed) - 21(Fri), 2004 for 3 days at Tokyo Big Sight, Japan - The 3rd INTERNATIONAL BIO EXPO JAPAN 2004, together with the INTERPHEX JAPAN
INTERNATIONAL BIO EXPO JAPAN expands again, welcome some 450 exhibitors, presenting their latest products, technologies and services.
Last year, 13,591 professionals visited INTERNATIONAL BIO EXPO JAPAN.
It is expected that some 15,000 professionals attend from Japan and all over the world.
List of exhibitors includes: XENOTECH LLC

9. June 15, 2004 - 7th International Conference on Drug-Drug Interactions
https://www.isciencex.com/DDI-2004%20program%20FINAL.htm

10:30 AM – 11:15 AM
Immortalized and Fresh Human Hepatocytes: Use and Performance in Metabolism, Induction and Toxicity Screening (Andrew Parkinson, XenoTech, Lenexa, KS) Human hepatocytes play several key roles in preclinical drug development, including assessment of enzyme induction, cellular toxicity, drug metabolism and species comparisons. This presentation compares fresh and cryopreserved human hepatocytes to a new human hepatocyte cell line that has the potential to solve the problem of supply and variability that restrict the use of human hepatocytes for enzyme induction and other in vitro screening.

11:15 AM – 12:00 PM

Predicting Clinical DDI Arising from CYP3A4 Induction Using In Vitro Data: Studies with the Fa2N-4 Immortalized Hepatocyte Line (Sharon L. Ripp, Pfizer Global Research & Development; Groton, CT) The Fa2N-4 human hepatocyte line, when treated with prototypical inducers, shows a robust induction of CYP3A4 mRNA and enzymatic activity. We are examining ways to use this in vitro induction data to predict clinical DDI due to CYP3A4. One possibility is to combine potency and efficacy data from Fa2N-4 cells with efficacious plasma concentrations to assess in vivo induction potential. Studies assessing the validity of this approach using prototypical inducers will be discussed.

10. 7th International ISSX Meeting
August 29 - September 2, 2004
Vancouver, BC, Canada
Go to ISSX

11. The Seventh Annual International Conference on Drug Metabolism/Applied Pharmacokinetics
Devil’s Head Lodge, Merrimac, WI
September 13-17, 2004
Wednesday, September 15
9:30 Wine and Cheese Reception
Sponsored by Xenotech LLC
Lenexa, KS

12. AAPS (November 7 - 11, 2004)
http://www.aapspharmaceutica.com/meetings/annualmeet/am04/
XenoTech - booth 202 (at the main entrance)


http://ragingbull.lycos.com/mboard/boards.cgi?board=EXTI&read=25667

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.